Remote Ischaemic Conditioning in STEMI Patients in Sub-Saharan AFRICA: Rationale and Study Design for the RIC-AFRICA Trial
| dc.contributor.author | Lukhna, Kishal | |
| dc.contributor.author | Mutyaba, Arthur | |
| dc.contributor.author | Kiggundu, Brian | |
| dc.contributor.author | Variava, Ebrahim | |
| dc.contributor.author | Ntsekhe, Mpiko | |
| dc.date.accessioned | 2025-08-08T08:12:12Z | |
| dc.date.available | 2025-08-08T08:12:12Z | |
| dc.date.issued | 2021-11-05 | |
| dc.description.abstract | Despite evidence of myocardial infarct size reduction in animal studies, remote ischaemic conditioning (RIC) failed to improve clinical outcomes in the large CONDI-2/ERIC-PPCI trial. Potential reasons include that the predominantly low-risk study participants all received timely optimal reperfusion therapy by primary percutaneous coronary intervention (PPCI). Whether RIC can improve clinical outcomes in higher-risk STEMI patients in environments with poor access to early reperfusion or PPCI will be investigated in the RIC-AFRICA trial. The RIC-AFRICA study is a sub-Saharan African multi-centre, randomized, double-blind, sham-controlled clinical trial designed to test the impact of RIC on the composite endpoint of 30-day mortality and heart failure in 1200 adult STEMI patients without access to PPCI. Randomized participants will be stratified by whether or not they receive thrombolytic therapy within 12 h or arrive outside the thrombolytic window (12–24 h). Participants will receive either RIC (four 5-min cycles of inflation [20 mmHg above systolic blood pressure] and deflation of an automated blood pressure cuff placed on the upper arm) or sham control (similar protocol but with low-pressure inflation of 20 mmHg and deflation) within 1 h of thrombolysis and applied daily for the next 2 days. STEMI patients arriving greater than 24 h after chest pain but within 72 h will be recruited to participate in a concurrently running independent observational arm. The RIC-AFRICA trial will determine whether RIC can reduce rates of death and heart failure in higher-risk sub-optimally reperfused STEMI patients, thereby providing a low-cost, non-invasive therapy for improving health outcomes. | |
| dc.identifier.citation | Lukhna, K., Hausenloy, D. J., Ali, A. S., Bajaber, A., Calver, A., Mutyaba, A., ... & Yellon, D. M. (2023). Remote ischaemic conditioning in STEMI patients in sub-Saharan AFRICA: rationale and study design for the RIC-AFRICA trial. Cardiovascular Drugs and Therapy, 37(2), 299-305. | |
| dc.identifier.other | https://doi.org/10.1007/s10557-021-07283-y | |
| dc.identifier.uri | https://nru.uncst.go.ug/handle/123456789/12000 | |
| dc.language.iso | en | |
| dc.publisher | Cardiovascular Drugs and Therapy | |
| dc.title | Remote Ischaemic Conditioning in STEMI Patients in Sub-Saharan AFRICA: Rationale and Study Design for the RIC-AFRICA Trial | |
| dc.type | Article |